The Council of Scientific and Industrial Analysis (CSIR) will undertake a two-arm phase-II medical trial to evaluate the security and efficacy of the drug Colchicine for the therapy of Covid-19 sufferers.
Colchicine is used for treating gout and associated inflammatory situations. The drug is anticipated to be an essential therapeutic intervention for Covid sufferers with cardiac co-morbidities.
Quite a lot of international research have confirmed now that cardiac issues throughout course of Covid-19 infections and post-Covid syndrome are resulting in lack of many lives, and it’s important to search for new or repurposed medication.
India is among the largest producers of this key drug Colchicine and if profitable, it will likely be made out there to the sufferers at an inexpensive price.
CSIR and Hyderabad-based Laxai Life Sciences Pvt Ltd have been given regulatory approval by Medication Controller Normal of India (DCGI) to undertake a two-arm phase-II